Asthma – Pipeline Review, H1 2012

Published by: Global Markets Direct

Published: Feb. 27, 2012 - 288 Pages

Table of Contents

Introduction

Global Markets Direct Report Coverage

Asthma Overview

Therapeutics Development

An Overview of Pipeline Products for Asthma

Asthma Therapeutics under Development by Companies

Asthma Therapeutics under Investigation by Universities/Institutes

Late Stage Products

Comparative Analysis

Mid Clinical Stage Products

Comparative Analysis

Early Clinical Stage Products

Comparative Analysis

Discovery and Pre-Clinical Stage Products

Comparative Analysis

Asthma Therapeutics – Products under Development by Companies

Asthma Therapeutics – Products under Investigation by Universities/Institutes

Companies Involved in Asthma Therapeutics Development

Johnson & Johnson

Boehringer Ingelheim GmbH

F. Hoffmann-La Roche Ltd.

Kyowa Hakko Kirin Co., Ltd.

Abbott Laboratories

Amgen Inc.

AstraZeneca PLC

GlaxoSmithKline plc

Genentech, Inc.

Biotec Pharmacon ASA

MedImmune LLC

Merck & Co., Inc.

United Biomedical, Inc.

Dainippon Sumitomo Pharma Co., Ltd.

SkyePharma PLC

Acusphere, Inc.

Novagali Pharma SA

Novartis AG

Actelion Ltd

ALK-Abello A/S

Cephalon, Inc.

Chiesi Farmaceutici SpA

Forest Laboratories, Inc.

Glenmark Pharmaceuticals Ltd.

Kissei Pharmaceutical Co., Ltd.

Ono Pharmaceutical Co., Ltd.

Orion Corporation

Rigel Pharmaceuticals, Inc.

PARI Pharma GmbH

Icagen Inc

Antisense Therapeutics Limited

Idera Pharmaceuticals, Inc.

Lotus Pharmaceuticals, Inc.

Almirall, S.A.

Compugen Ltd.

Pacgen Biopharmaceuticals Corporation

Palatin Technologies, Inc.

Pharmaxis Ltd.

MAP Pharmaceuticals, Inc.

Alexion Pharmaceuticals, Inc.

Cytokinetics, Inc

Yuhan Corporation

Regeneron Pharmaceuticals, Inc.

SciClone Pharmaceuticals, Inc.

Array BioPharma Inc.

Dynavax Technologies Corporation

Phytopharm Plc

Stallergenes S.A.

Cytos Biotechnology AG

Ahn-Gook Pharmaceutical Co., Ltd.

Biotie Therapies Corp.

Neurim Pharmaceuticals (1991) Ltd.

Synairgen plc

Orexo AB

e-Therapeutics plc

InDex Pharmaceuticals AB

Verona Pharma Plc

Advinus Therapeutics Pvt. Ltd.

Affimed Therapeutics AG

Alba Therapeutics Corporation

Allergopharma Joachim Ganzer KG

Immupharma Plc

Palau Pharma S.A

7TM Pharma A/S

Pieris AG

Respiratorius AB

Cosmix Molecular Biologicals GmbH

Aquinox Pharmaceuticals Inc.

Circassia Holdings Ltd.

Funxional Therapeutics Ltd

ZaBeCor Pharmaceuticals

Promedior, Inc.

Oxagen Limited

Clinquest Group, B.V.

Heat Biologics, Inc.

Pulmatrix, Inc.

Opsona Therapeutics Ltd.

Rottapharm SpA

Amira Pharmaceuticals, Inc.

Indus Biotech Private Limited

AIM Therapeutics Inc.

Hydra Biosciences, Inc.

NovImmune SA

Txcell SA

Theraclone Sciences, Inc.

Vantia Therapeutics

Biotica Technology Ltd

Inverseon, Inc.

Xencor, Inc.

Targacept, Inc.

BaroFold, Inc.

Sparsha Pharma International Pvt. Ltd.

KaloBios Pharmaceuticals, Inc.

AB Science

Resolvyx Pharmaceuticals, Inc

Adamis Pharmaceuticals Corporation

Aerovance, Inc.

NexBio, Inc.

Medigreen Biotechnology Corporation

Endacea, Inc.

Kemin Industries, Inc.

Sun Pharmaceutical Industries, Inc.

Asmacure Limited

Yoo Young Pharmaceutical Co., Ltd.

Cellceutix Pharmaceuticals, Inc.

Interprotein Corporation

ISU ABXIS Co.,Ltd.

N30 Pharmaceuticals

Eurofarma

Mankind Pharma Limited

Immune Technologies and Medicine

Asklepion Pharmaceuticals, LLC.

Asthma – Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Combination Products

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

Daliresp - Drug Profile

Indacaterol - Drug Profile

Xolair - Drug Profile

Cinquil - Drug Profile

Flutiform - Drug Profile

Flutiform - Drug Profile

Relovair - Drug Profile

Achipex - Drug Profile

ETX9101 - Drug Profile

Mitizax - Drug Profile

MAP0010 - Drug Profile

Spiriva - Drug Profile

GSK685698 - Drug Profile

Atorvastatin - Drug Profile

Clarithromycin - Drug Profile

Biaxin + Flovent - Drug Profile

Budesonide + Formoterol - Drug Profile

AB1010 - Drug Profile

Staloral - Drug Profile

Lansoprazole - Drug Profile

Azithromycin - Drug Profile

BDP + Salbutamol HFA pMDI - Drug Profile

RhuMab-E25 - Drug Profile

Omalizumab - Drug Profile

Montelukast - Drug Profile

Montelukast - Drug Profile

Grazax - Drug Profile

Terbutaline Turbuhaler - Drug Profile

Ciclesonide - Drug Profile

Budesonide - Drug Profile

Rosiglitazone - Drug Profile

Theophylline - Drug Profile

Nedocromil - Drug Profile

Symbicort - Drug Profile

Acaroid - Drug Profile

Formoterol + Fluticasone - Drug Profile

Salmeterol + Fluticasone - Drug Profile

Beclomethasone Dipropionate + Albuterol Sulfate - Drug Profile

Salmeterol + Beclomethasone - Drug Profile

Tiotropium Bromide + Salmeterol Xinofoate + Beclomethasone Dipropionate - Drug Profile

Prednisolone - Drug Profile

Simvastatin - Drug Profile

Beclomethasone Dipropionate - Drug Profile

Beclomethasone Dipropionate - Drug Profile

Fluticasone propionate + Montelukast - Drug Profile

Simvastatin + Corticosteroids - Drug Profile

CR-2039 - Drug Profile

Xolair + Depigoid - Drug Profile

Budesonide + Formoterol - Drug Profile

Fluticasone-Salmeterol Formulation - Drug Profile

Budesonide - Drug Profile

Sereflo - Drug Profile

Tulobuterol Patch - Drug Profile

Anti-Inflammatory - Drug Profile

Formoterol - Drug Profile

Acebrophylline + Montelukast - Drug Profile

IP-033 - Drug Profile

Inactivated Mycobacterium Phlei - Drug Profile

Asthma Therapeutics – Drug Profile Updates

Asthma Therapeutics – Discontinued Products

Asthma Therapeutics - Dormant Products

Asthma – Product Development Milestones

Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products Under Development for Asthma, H1 2012

Products under Development for Asthma – Comparative Analysis, H1 2012

Number of Products under Development by Companies, H1 2012

Number of Products under Development by Companies, H1 2012 (Contd..1)

Number of Products under Development by Companies, H1 2012 (Contd..2)

Number of Products under Development by Companies, H1 2012 (Contd..3)

Number of Products under Development by Companies, H1 2012 (Contd..4)

Number of Products under Development by Companies, H1 2012 (Contd..5)

Number of Products under Development by Companies, H1 2012 (Contd..6)

Number of Products under Development by Companies, H1 2012 (Contd..7)

Number of Products under Development by Companies, H1 2012 (Contd..8)

Number of Products under Investigation by Universities/Institutes, H1 2012

Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..1)

Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..2)

Comparative Analysis by Late Stage Development, H1 2012

Comparative Analysis by Mid Clinical Stage Development, H1 2012

Comparative Analysis by Early Clinical Stage Development, H1 2012

Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2012

Products under Development by Companies, H1 2012

Products under Development by Companies, H1 2012 (Contd..1)

Products under Development by Companies, H1 2012 (Contd..2)

Products under Development by Companies, H1 2012 (Contd..3)

Products under Development by Companies, H1 2012 (Contd..4)

Products under Development by Companies, H1 2012 (Contd..5)

Products under Development by Companies, H1 2012 (Contd..6)

Products under Development by Companies, H1 2012 (Contd..7)

Products under Development by Companies, H1 2012 (Contd..8)

Products under Development by Companies, H1 2012 (Contd..9)

Products under Development by Companies, H1 2012 (Contd..10)

Products under Development by Companies, H1 2012 (Contd..11)

Products under Development by Companies, H1 2012 (Contd..12)

Products under Investigation by Universities/Institutes, H1 2012

Products under Investigation by Universities/Institutes, H1 2012 (Contd..1)

Products under Investigation by Universities/Institutes, H1 2012 (Contd..2)

Products under Investigation by Universities/Institutes, H1 2012 (Contd..3)

Johnson & Johnson, H1 2012

Boehringer Ingelheim GmbH, H1 2012

F. Hoffmann-La Roche Ltd., H1 2012

Kyowa Hakko Kirin Co., Ltd., H1 2012

Abbott Laboratories, H1 2012

Amgen Inc., H1 2012

AstraZeneca PLC, H1 2012

GlaxoSmithKline plc, H1 2012

Genentech, Inc., H1 2012

Biotec Pharmacon ASA, H1 2012

MedImmune LLC, H1 2012

Merck & Co., Inc., H1 2012

United Biomedical, Inc., H1 2012

Dainippon Sumitomo Pharma Co., Ltd., H1 2012

SkyePharma PLC, H1 2012

Acusphere, Inc., H1 2012

Novagali Pharma SA, H1 2012

Novartis AG, H1 2012

Actelion Ltd, H1 2012

ALK-Abello A/S, H1 2012

Cephalon, Inc., H1 2012

Chiesi Farmaceutici SpA, H1 2012

Forest Laboratories, Inc., H1 2012

Glenmark Pharmaceuticals Ltd., H1 2012

Kissei Pharmaceutical Co., Ltd., H1 2012

Ono Pharmaceutical Co., Ltd., H1 2012

Orion Corporation, H1 2012

Rigel Pharmaceuticals, Inc., H1 2012

PARI Pharma GmbH, H1 2012

Icagen Inc, H1 2012

Antisense Therapeutics Limited, H1 2012

Idera Pharmaceuticals, Inc., H1 2012

Lotus Pharmaceuticals, Inc., H1 2012

Almirall, S.A., H1 2012

Compugen Ltd., H1 2012

Pacgen Biopharmaceuticals Corporation, H1 2012

Palatin Technologies, Inc., H1 2012

Pharmaxis Ltd., H1 2012

MAP Pharmaceuticals, Inc., H1 2012

Alexion Pharmaceuticals, Inc., H1 2012

Cytokinetics, Inc, H1 2012

Yuhan Corporation, H1 2012

Regeneron Pharmaceuticals, Inc., H1 2012

SciClone Pharmaceuticals, Inc., H1 2012

Array BioPharma Inc., H1 2012

Dynavax Technologies Corporation, H1 2012

Phytopharm Plc, H1 2012

Stallergenes S.A., H1 2012

Cytos Biotechnology AG, H1 2012

Ahn-Gook Pharmaceutical Co., Ltd., H1 2012

Biotie Therapies Corp., H1 2012

Neurim Pharmaceuticals (1991) Ltd., H1 2012

Synairgen plc, H1 2012

Orexo AB, H1 2012

e-Therapeutics plc, H1 2012

InDex Pharmaceuticals AB, H1 2012

Verona Pharma Plc, H1 2012

Advinus Therapeutics Pvt. Ltd., H1 2012

Affimed Therapeutics AG, H1 2012

Alba Therapeutics Corporation, H1 2012

Allergopharma Joachim Ganzer KG, H1 2012

Immupharma Plc, H1 2012

Palau Pharma S.A, H1 2012

7TM Pharma A/S, H1 2012

Pieris AG, H1 2012

Respiratorius AB, H1 2012

Cosmix Molecular Biologicals GmbH, H1 2012

Aquinox Pharmaceuticals Inc., H1 2012

Circassia Holdings Ltd., H1 2012

Funxional Therapeutics Ltd, H1 2012

ZaBeCor Pharmaceuticals, H1 2012

Promedior, Inc., H1 2012

Oxagen Limited, H1 2012

Clinquest Group, B.V., H1 2012

Heat Biologics, Inc., H1 2012

Pulmatrix, Inc., H1 2012

Opsona Therapeutics Ltd., H1 2012

Rottapharm SpA, H1 2012

Amira Pharmaceuticals, Inc., H1 2012

Indus Biotech Private Limited, H1 2012

AIM Therapeutics Inc., H1 2012

Hydra Biosciences, Inc., H1 2012

NovImmune SA, H1 2012

Txcell SA, H1 2012

Theraclone Sciences, Inc., H1 2012

Vantia Therapeutics, H1 2012

Biotica Technology Ltd, H1 2012

Inverseon, Inc., H1 2012

Xencor, Inc., H1 2012

Targacept, Inc., H1 2012

BaroFold, Inc., H1 2012

Sparsha Pharma International Pvt. Ltd., H1 2012

KaloBios Pharmaceuticals, Inc., H1 2012

AB Science, H1 2012

Resolvyx Pharmaceuticals, Inc, H1 2012

Adamis Pharmaceuticals Corporation, H1 2012

Aerovance, Inc., H1 2012

NexBio, Inc., H1 2012

Medigreen Biotechnology Corporation, H1 2012

Endacea, Inc., H1 2012

Kemin Industries, Inc., H1 2012

Sun Pharmaceutical Industries, Inc., H1 2012

Asmacure Limited, H1 2012

Yoo Young Pharmaceutical Co., Ltd., H1 2012

Cellceutix Pharmaceuticals, Inc., H1 2012

Interprotein Corporation, H1 2012

ISU ABXIS Co.,Ltd., H1 2012

N30 Pharmaceuticals, H1 2012

Eurofarma, H1 2012

Mankind Pharma Limited, H1 2012

Immune Technologies and Medicine, H1 2012

Asklepion Pharmaceuticals, LLC., H1 2012

Assessment by Monotherapy Products, H1 2012

Assessment by Combination Products, H1 2012

Assessment by Stage and Route of Administration, H1 2012

Assessment by Stage and Molecule Type, H1 2012

Asthma Therapeutics – Drug Profile Updates

Asthma Therapeutics – Discontinued Products

Asthma Therapeutics – Discontinued Products (Contd..1)

Asthma Therapeutics – Discontinued Products (Contd..2)

Asthma Therapeutics – Discontinued Products (Contd..3)

Asthma Therapeutics – Discontinued Products (Contd..4)

Asthma Therapeutics – Discontinued Products (Contd..5)

Asthma Therapeutics – Dormant Products

Asthma Therapeutics – Dormant Products (Contd..1)

Asthma Therapeutics – Dormant Products (Contd..2)

Asthma Therapeutics – Dormant Products (Contd..3)

Asthma Therapeutics – Dormant Products (Contd..4)

Asthma Therapeutics – Dormant Products (Contd..5)

Asthma Therapeutics – Dormant Products (Contd..6)

Asthma Therapeutics – Dormant Products (Contd..7)

Asthma Therapeutics – Dormant Products (Contd..8)

Asthma Therapeutics – Dormant Products (Contd..9)

Asthma Therapeutics – Dormant Products (Contd..10)

Asthma Therapeutics – Dormant Products (Contd..11)

Asthma Therapeutics – Dormant Products (Contd..12)

Asthma Therapeutics – Dormant Products (Contd..13)

List of Figures

Number of Products under Development for Asthma, H1 2012

Products under Development for Asthma – Comparative Analysis, H1 2012

Products under Development by Companies, H1 2012

Products under Investigation by Universities/Institutes, H1 2012

Late Stage Products, H1 2012

Mid Clinical Stage Products, H1 2012

Early Clinical Stage Products, H1 2012

Discovery and Pre-Clinical Stage Products, H1 2012

Assessment by Monotherapy Products, H1 2012

Assessment by Combination Products, H1 2012

Assessment by Route of Administration, H1 2012

Assessment by Stage and Route of Administration, H1 2012

Assessment by Molecule Type, H1 2012

Assessment by Stage and Molecule Type, H1 2012

Abstract

• A snapshot of the global therapeutic scenario for Asthma.
• A review of the Asthma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
• Coverage of products based on various stages of development ranging from discovery till registration stages.
• A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
• Coverage of the Asthma pipeline on the basis of route of administration and molecule type.
• Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
• Key discontinued pipeline projects.
• Latest news and deals relating to the products.

• Identify and understand important and diverse types of therapeutics under development for Asthma.
• Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
• Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
• Devise corrective measures for pipeline projects by understanding Asthma pipeline depth and focus of Asthma therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 400,000 market research reports, company profiles and country profiles from over 720 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.